To conclude, by profiling key HR pathway proteins in SOC patients we have demonstrated that protein expression changes of MRE11 and BRCA1 are strongly associated with serous ovarian cancer in late clinical stage, suggesting their potential utility as prognostic tools in the analysis of tumor biopsies or circulating tumor cells. This evidence concerns the gene BRCA1 and ovarian serous adenocarcinoma.